Zurueck zur Suche

Reporte zur Charge U021561

Verknuepft ueber VAERS_ID mit VAERSDATA, Vax und Symptoms

24Reporte angezeigt
0Todesfaelle
1Hospitalisiert
0Lebensbedrohlich
0Bleibende Schaeden
MI 5 IN 3 NY 2 MA 2 KY 2 TN 2 NC 1 MO 1 PA 1 VT 1 NJ 1 OH 1

VAERS 2595690

MERCK & CO. INC. · HEP A (VAQTA) · Charge U021561

kritisch
Staat
MI
Alter
45,0
Geschlecht
F
Eingang
13.03.2023
Impfdatum
07.02.2022
Beginn
10.02.2023
Tage bis Beginn
368,0
Dosis
1
Route/Site
- / -
Tod: unbekannt Lebensbedrohlich: unbekannt Hospital: ja Disable: unbekannt ER: unbekannt Erholt: ja
Acute myeloid leukaemia Acute respiratory failure Adrenal adenoma Biopsy bone marrow abnormal Blood aldosterone Blood catecholamines Blood culture negative Blood smear test abnormal COVID-19 Central venous catheterisation Chemotherapy Computerised tomogram abdomen abnormal Computerised tomogram abnormal Computerised tomogram neck Computerised tomogram thorax abnormal Cortisol free urine normal Dehydroepiandrosterone test Diuretic therapy

Symptomtext

Primary Care Physician at Discharge: DO Hematologist/Oncologist: Dr. Admission Date: 2/10/2023 Discharge Date: 03/11/2023 Patient's Discharge Disposition: Home in stable condition. This is a a 46 yo female with a history of ADHD who presented to the ED on 2/10/23 with findings of elevated WBC and concerns for acute leukemia. Peripheral smear on 2/10 was consistent with acute leukemia. On presentation she had anterior cervical lymphadenopathy and concerns for sinusitis and tonsillitis. CT neck 2/10 showed several mildly enlarged level 1 and 2 lymph nodes as well as mildly prominent retropharyngeal lymph nodes findings concerning for possible tonsillitis/sinusitis. The patient was found to be positive for Covid-19 on admisison. She was treated with dex 2/10-2/15 and Remdesivir and remained stable. Bone marrow biopsy done 2/13 (in IR) was positive for AML, normal kayotype, FLT3-TKD mutated and NPM! Mutated. Panorex with no acute findings. ECHO with LVEF 64%. Hepatitis and HIV were negative. HLA typing was sent. PICC line was placed 2/15. She started induction chemo on 2/15/23 with 7+3 and then started Rydapt/Midostaurin D8-21. Day 21 IR bone marrow done 3/7 showed approximately 80% cellular bone marrow, no evidence of leukemia. She did have recurrent sinus pain and neck swelling. CT sinus/neck on 3/5 showed pansinusitis, possible otomastoiditis. ENT did see her and did not have concern for acute mastoididits. Blood cultures were negative. ID was consulted. She was on broad spectrum antibiotics. . During her nadir she also had neutropenic fevers and recurrent acute hypoxemic respiratory failure. CT thorax 3/5 showed diffuse bilateral interstitial ground glass opacities. ECHO 3/5/23 showed an EF of 55%, previously was 64%. Pulmonary was consulted and felt respiratory failure related to fluid overload vs TRALI/TACO with frequent transfusions. She was started on IV lasix BID and had good results and improvement with diuresis. She developed a rash thought to be related to cefepime and ultimately improved once antibiotics were changed. She was treated with with merrem, vancomycin, micafungin, and nystatin through 3/10 when her counts recovered. ID recommended observing off antibiotics. At discharge they recommended ppx acyclovir but with negative bone marrow biopsy from Day 21 antifungal medications. She was also on IV steroids which will be quickly tapered down at discharge. She has been weaned off O2 inpatient. The patient's counts recovered with no evidence of leukemia on D21 Bone marrow biopsy the patient is stable for discharge home today. PICC line was removed. She lives in the area and would like to get labs on Tuesdays/Thursdays in the office but will follow-up with Dr. at clinic. Per weekend attending she will need another IR bone marrow biopsy next week now that her counts have recovered. We will arrange outpatient IR bone marrow biopsy and f/u with Dr. after that is done. She is discharging home in stable condition. Incidental findings this admission: -CT sinuses 3/5 showed prominence of the sella- probably related to empty sella-- patient was asymptomatic with these findings. -CT AP 2/10 showed splenomegaly, multiple vascular lesions throughout liver-likely hemangiomas and MRI abdomen 2/14 showed focal nodular hyperplasia in the right lobe of liver. Has had Mild LFT elevation, but stable. -CT AP 2/14 showed complex partially exophytic cyst at the upper pole of right kidney, ? Bosniak III cyst. Urology plans f/u in 4 months to discuss further treatment plan. -MRI 2/14 right adrenal adenoma- urology evaluated-- 24h urine cortisol (<3.4), plasma fractionated metanephrines (<0.20), DHEA sulfate (low at 12.4) and aldosterone (10.7) level

Weitere VAERSDATA-Felder
Praegender Schweregrund
Acute respiratory failure
Hospital-Tage
29,0
Labordaten
-
Aktuelle Erkrankungen
None
Vorgeschichte
Leukocytosis Acute myeloid leukemia not having achieved remission Neutropenic fever Morbid obesity with body mass index (BMI) of 50.0 to 59.9 in adult Tobacco use Adult ADHD Mucositis due to chemotherapy Alternating constipation and diarrhea Counseling regarding advanced care planning and goals of care Dysphagia with left side facial/neck swelling. Acute respiratory failure with hypoxia hx of COVID-19 Bilateral pulmonary infiltrates on Imaging
Andere Medikamente
acyclovir (ZOVIRAX) 200 MG capsule amLODIPine (NORVASC) 2.5 MG tablet benzonatate (TESSALON) 100 MG capsule furosemide (LASIX) 20 MG tablet guaiFENesin (MUCINEX) 600 MG 12 hr tablet lidocaine viscous (XYLOCAINE) 2 % solution loperamide (IMO
Allergien
None
Vorherige Impfungen
-

VAERS 2266942

MERCK & CO. INC. · HEP A (VAQTA) · Charge U021561

mild
Staat
-
Alter
36,0
Geschlecht
F
Eingang
07.05.2022
Impfdatum
03.05.2022
Beginn
04.05.2022
Tage bis Beginn
1,0
Dosis
1
Route/Site
IM / LA
Tod: unbekannt Lebensbedrohlich: unbekannt Hospital: unbekannt Disable: unbekannt ER: unbekannt Erholt: unbekannt
Headache Pain in extremity Peripheral swelling Pyrexia Tissue injury

Symptomtext

Patient began to have fever, headache, arm swelling on 5/4/22. Then presented with deep tissue injury and arm pain that began on 5/6/22 .

Weitere VAERSDATA-Felder
Praegender Schweregrund
Headache
Hospital-Tage
-
Labordaten
-
Aktuelle Erkrankungen
-
Vorgeschichte
-
Andere Medikamente
-
Allergien
-
Vorherige Impfungen
-

VAERS 2683221

MERCK & CO. INC. · HEP A (VAQTA) · Charge U021561

gering
Staat
NC
Alter
87,0
Geschlecht
M
Eingang
18.09.2023
Impfdatum
21.02.2023
Beginn
21.02.2023
Tage bis Beginn
0,0
Dosis
UNK
Route/Site
OT / -
Tod: unbekannt Lebensbedrohlich: unbekannt Hospital: unbekannt Disable: unbekannt ER: unbekannt Erholt: nein
Expired product administered

Symptomtext

No additional AE reported.; Patient was administered expired VAQTA; This spontaneous report was received from Pharmacist and refers to an unknown patient of an unknown age or gender. The patient's medical history, concurrent conditions, concomitant therapies and previous drugs reactions or allergies were not reported. On 21-FEB-2023, the patient was vaccinated with an expired vaccine of hepatitis a vaccine, inactivated (VAQTA) lot #U021561, expiration date: 14-JAN-2023, administered for prophylaxis (strength, and route of administration were not provided) (Expired vaccine used), it was stated that No Temperature Excursion reported for Affected Product prior the administration of the vaccine. No additional adverse event was reported. This case was considered as non-valid due to lack of patient identifiers. Follow-up information has been received from the pharmacist on 11-SEP-2023. The patient's demographic information was updated. The case was regarding a 87-years-old male patient. The patient's pertinent medical history, previous drug reactions or allergies and concomitant medications were not reported. The previously reported expired dose of Hepatitis A Vaccine, Inactivated (VAQTA) was administered intramuscularly. It was reported the patient and primary physician were informed of the incident and that the patient had no side effect or adverse reactions from the expired dose administered.

Weitere VAERSDATA-Felder
Praegender Schweregrund
Expired product administered
Hospital-Tage
-
Labordaten
-
Aktuelle Erkrankungen
-
Vorgeschichte
-
Andere Medikamente
-
Allergien
-
Vorherige Impfungen
-

VAERS 2603809

MERCK & CO. INC. · HEP A (VAQTA) · Charge U021561

gering
Staat
MO
Alter
42,0
Geschlecht
F
Eingang
03.04.2023
Impfdatum
16.03.2023
Beginn
16.03.2023
Tage bis Beginn
0,0
Dosis
UNK
Route/Site
- / -
Tod: unbekannt Lebensbedrohlich: unbekannt Hospital: unbekannt Disable: unbekannt ER: unbekannt Erholt: ja
Expired product administered No adverse event

Symptomtext

Expired vaccine administered

Weitere VAERSDATA-Felder
Praegender Schweregrund
Expired product administered
Hospital-Tage
-
Labordaten
-
Aktuelle Erkrankungen
-
Vorgeschichte
-
Andere Medikamente
-
Allergien
-
Vorherige Impfungen
-

VAERS 2605534

MERCK & CO. INC. · HEP A (VAQTA) · Charge U021561

gering
Staat
PA
Alter
-
Geschlecht
U
Eingang
29.03.2023
Impfdatum
10.03.2023
Beginn
10.03.2023
Tage bis Beginn
0,0
Dosis
UNK
Route/Site
- / -
Tod: unbekannt Lebensbedrohlich: unbekannt Hospital: unbekannt Disable: unbekannt ER: unbekannt Erholt: nein
Expired product administered No adverse event

Symptomtext

No additional AE; an expired dose of VAQTA to a patient on 10MAR2023; This spontaneous report was received from a Medical Assistant and referred to a patient of unknown age and gender. The patient's medical history, concurrent conditions, concomitant therapies, drug reactions and allergies were not reported. On 10-MAR-2023, the patient was vaccinated with an expired dose of hepatitis a vaccine, inactivated (VAQTA) intramuscular injection, 1 dosage form, lot #U021561, expiration date: 14-JAN-2023, administered for prophylaxis (strength, and route of administration were not provided) (expired product administered). The reporter confirmed the product was not involved in a temperature excursion and was stored according to the recommended storage range until administration. No additional adverse event was reported.

Weitere VAERSDATA-Felder
Praegender Schweregrund
Expired product administered
Hospital-Tage
-
Labordaten
-
Aktuelle Erkrankungen
-
Vorgeschichte
-
Andere Medikamente
-
Allergien
-
Vorherige Impfungen
-

VAERS 2599381

MERCK & CO. INC. · HEP A (VAQTA) · Charge U021561

gering
Staat
NY
Alter
20,0
Geschlecht
M
Eingang
20.03.2023
Impfdatum
23.02.2023
Beginn
23.02.2023
Tage bis Beginn
0,0
Dosis
2
Route/Site
OT / -
Tod: unbekannt Lebensbedrohlich: unbekannt Hospital: unbekannt Disable: unbekannt ER: unbekannt Erholt: nein
Expired product administered No adverse event

Symptomtext

No additional AEs; LPN calling to report that expired lot of VAQTA ADULT (EXP 1/14/2023) was administered on 2/23/2023; This spontaneous report was received from licensed practical nurse and refers to a 20-year-old male.The patients' concurrent conditions, medical history, concomitant therapies and historical drug were not provided. On an unknown date, the patient was vaccinated with hepatitis a vaccine, inactivated (VAQTA) intramuscular injection, 1 milliliter, lot #U021561, expiration date: 14-JAN-2023 (expired product administered), administered intramuscularly for prophylaxis (strength was not provided). No additional adverse event was reported.

Weitere VAERSDATA-Felder
Praegender Schweregrund
Expired product administered
Hospital-Tage
-
Labordaten
-
Aktuelle Erkrankungen
-
Vorgeschichte
-
Andere Medikamente
-
Allergien
-
Vorherige Impfungen
-

VAERS 2574432

GLAXOSMITHKLINE BIOLOGICALS · HEP A (HAVRIX) · Charge U021561

gering
Staat
VT
Alter
-
Geschlecht
U
Eingang
02.02.2023
Impfdatum
26.01.2023
Beginn
26.01.2023
Tage bis Beginn
0,0
Dosis
UNK
Route/Site
- / -
Tod: unbekannt Lebensbedrohlich: unbekannt Hospital: unbekannt Disable: unbekannt ER: unbekannt Erholt: nein
Expired product administered

Symptomtext

administered an expired dose; This case was reported by a other health professional via call center representative and described the occurrence of expired vaccine used in a patient who received HAV (Havrix adult) (batch number U021561, expiry date 14th January 2023) for prophylaxis. On 26th January 2023, the patient received Havrix adult. On 26th January 2023, unknown after receiving Havrix adult, the patient experienced expired vaccine used. On an unknown date, the outcome of the expired vaccine used was unknown. Additional Information: GSK Receipt Date: 26-JAN-2023 Reporter's Comments: The reporter mentioned that one of his/her nurses inadvertently administered an expired Adult Hepatitis A vaccine. The reporter was looking for guidance as to whether they need to re-vaccinate the patient. No other details provided The reporter consented to follow up via web form. No other details provided. Additional Supportive Information: the patient inadvertently received expired dose of Hepatitis A adult vaccine.

Weitere VAERSDATA-Felder
Praegender Schweregrund
Expired product administered
Hospital-Tage
-
Labordaten
-
Aktuelle Erkrankungen
-
Vorgeschichte
-
Andere Medikamente
-
Allergien
-
Vorherige Impfungen
-

VAERS 2573055

MERCK & CO. INC. · HEP A (VAQTA) · Charge U021561

gering
Staat
NJ
Alter
66,0
Geschlecht
M
Eingang
01.02.2023
Impfdatum
16.01.2023
Beginn
16.01.2023
Tage bis Beginn
0,0
Dosis
UNK
Route/Site
- / -
Tod: unbekannt Lebensbedrohlich: unbekannt Hospital: unbekannt Disable: unbekannt ER: unbekannt Erholt: nein
Expired product administered

Symptomtext

No additional AE/PQC reported; expired VAQTA was administered to a patient; This spontaneous report was received from a medical assistant and referred to a 66-year-old male patient. The patient's medical history, concurrent conditions, concomitant therapies and drug reaction/allergies were not reported. On 16-JAN-2023, the expired hepatitis a vaccine, inactivated (VAQTA) intramuscular injection was administered to the patient for prophylaxis (lot #U021561, expiration date: 14-JAN-2023; strength, dose and route of administration were not provided) (expired product administered). No additional adverse event (AE) was reported.

Weitere VAERSDATA-Felder
Praegender Schweregrund
Expired product administered
Hospital-Tage
-
Labordaten
-
Aktuelle Erkrankungen
-
Vorgeschichte
-
Andere Medikamente
-
Allergien
-
Vorherige Impfungen
-

VAERS 2572853

MERCK & CO. INC. · HEP A (VAQTA) · Charge U021561

gering
Staat
MA
Alter
-
Geschlecht
U
Eingang
01.02.2023
Impfdatum
-
Beginn
27.01.2023
Tage bis Beginn
-
Dosis
UNK
Route/Site
- / -
Tod: unbekannt Lebensbedrohlich: unbekannt Hospital: unbekannt Disable: unbekannt ER: unbekannt Erholt: nein
Expired product administered No adverse event

Symptomtext

No additional AE reported; Healthcare provider reports the administration of an expired dose of VAQTA to a patient on 27-JAN-2023.; This spontaneous report has been received from a medical assistant regarding a patient of unknown age and gender. Patient's pertinent medical history, drug reactions and allergies and concomitant medication were unknown by reporter. On 27-JAN-2023, the patient was vaccinated with an expired dose of Hepatitis A Vaccine, Inactivated (VAQTA), intramuscular injection, administered as prophylaxis, (dose, strength, route of administration, and anatomical location were not provided; lot number U021561 had been verified to be a valid number; expiration date was reported and established as 14-JAN-2023) (expired vaccine used). No additional adverse event reported.

Weitere VAERSDATA-Felder
Praegender Schweregrund
Expired product administered
Hospital-Tage
-
Labordaten
-
Aktuelle Erkrankungen
-
Vorgeschichte
-
Andere Medikamente
-
Allergien
-
Vorherige Impfungen
-

VAERS 2572664

MERCK & CO. INC. · HEP A (VAQTA) · Charge U021561

gering
Staat
IN
Alter
-
Geschlecht
U
Eingang
01.02.2023
Impfdatum
19.01.2023
Beginn
19.01.2023
Tage bis Beginn
0,0
Dosis
1
Route/Site
OT / -
Tod: unbekannt Lebensbedrohlich: unbekannt Hospital: unbekannt Disable: unbekannt ER: unbekannt Erholt: nein
Expired product administered No adverse event

Symptomtext

No additional AE reported; Medical assistant reports patient was accidently administered an expired dose of VAQTA on Jan 19, 2023. Product expired on Jan 14, 2023. Product had no prior temperature excursions. No further information provided. No additional AE reported. No PQC r; This spontaneous report was received from medical assistant and refers to an unknown age and gender patient. The patient's pertinent medical history, concurrent conditions, previous drug reactions allergies, and concomitant therapies were not reported. On 19-JAN-2023, the patient was accidently administered an expired dose of hepatitis a vaccine, inactivated (VAQTA) intramuscular injection, once, lot #U021561, expiration date: 14-JAN-2023, administered intramuscularly (strength, dose and indication were not provided) (expired product administered). It was mentioned that the product had no prior temperature excursions. No additional adverse event was reported.

Weitere VAERSDATA-Felder
Praegender Schweregrund
Expired product administered
Hospital-Tage
-
Labordaten
-
Aktuelle Erkrankungen
-
Vorgeschichte
-
Andere Medikamente
-
Allergien
-
Vorherige Impfungen
-

VAERS 2571286

MERCK & CO. INC. · HEP A (VAQTA) · Charge U021561

gering
Staat
KY
Alter
-
Geschlecht
U
Eingang
31.01.2023
Impfdatum
25.01.2023
Beginn
25.01.2023
Tage bis Beginn
0,0
Dosis
UNK
Route/Site
- / -
Tod: unbekannt Lebensbedrohlich: unbekannt Hospital: unbekannt Disable: unbekannt ER: unbekannt Erholt: nein
Expired product administered No adverse event

Symptomtext

No additional AE; Nurse Practitioner called and reported that a dose of VAQTA expired on 14JAN2023 and was administered on 25JAN2023. The product had no temperature excursions through date of administration. No additional AE reported. No PQC reported. No additional in; This spontaneous report was received from a nurse prescriber regarding a patient of unknown age and gender. The patient's medical history, concurrent conditions and concomitant therapies were not reported. On 25-JAN-2023, the patient was vaccinated with an expired dose of hepatitis a vaccine, inactivated (VAQTA) (lot #U021561, expiration date: 14-JAN-2023) (Expired product administered) for prophylaxis (strength, dose, dose number, anatomical location and route of administration were not provided). It was reported that the product had no temperature excursions and no additional adverse events were reported.

Weitere VAERSDATA-Felder
Praegender Schweregrund
Expired product administered
Hospital-Tage
-
Labordaten
-
Aktuelle Erkrankungen
-
Vorgeschichte
-
Andere Medikamente
-
Allergien
-
Vorherige Impfungen
-

VAERS 2570131

MERCK & CO. INC. · HEP A (VAQTA) · Charge U021561

gering
Staat
MA
Alter
23,0
Geschlecht
F
Eingang
30.01.2023
Impfdatum
16.01.2023
Beginn
16.01.2023
Tage bis Beginn
0,0
Dosis
UNK
Route/Site
OT / LA
Tod: unbekannt Lebensbedrohlich: unbekannt Hospital: unbekannt Disable: unbekannt ER: unbekannt Erholt: nein
Expired product administered No adverse event

Symptomtext

No additional AE; A HCP called to report that an expired dose of VAQTA was administered to a patient; This spontaneous report was received from a nurse, referring to a patient with unknown age and gender. The patient's concurrent conditions, medical history, concomitant therapy and drug reactions/allergies were not reported. On 16-JAN-2023, the patient was vaccinated with an expired dose of hepatitis a vaccine, inactivated (VAQTA) (lot number U021561 has been verified to be a valid lot number, expiration date was reported as 14-JAN-2023, dose, route and anatomical location were not provided) for prophylaxis (expired product administered). It has been confirmed no adverse effects were noted. No additional adverse event (AE) reported (no adverse event). This report was considered as non-valid due to the lack of the patient's identifiers. Follow up information has been received from the nurse, referring to a 23-year-old female patient on 24-JAN-2023. The patient had no ill effects from administration. On 16-JAN-2023, the patient was vaccinated with the correct hepatitis a vaccine, inactivated (VAQTA) (anatomical location was reported as left deltoid) via intramuscularly at private doctor's office/hospital. The hepatitis a vaccine, inactivated (VAQTA) expired two days prior to administration. No concerned with the efficacy of the vaccine administered. This report became to valid.

Weitere VAERSDATA-Felder
Praegender Schweregrund
Expired product administered
Hospital-Tage
-
Labordaten
-
Aktuelle Erkrankungen
-
Vorgeschichte
-
Andere Medikamente
-
Allergien
-
Vorherige Impfungen
-

VAERS 2568975

MERCK & CO. INC. · HEP A (VAQTA) · Charge U021561

gering
Staat
IN
Alter
-
Geschlecht
U
Eingang
27.01.2023
Impfdatum
24.01.2023
Beginn
24.01.2023
Tage bis Beginn
0,0
Dosis
UNK
Route/Site
- / -
Tod: unbekannt Lebensbedrohlich: unbekannt Hospital: unbekannt Disable: unbekannt ER: unbekannt Erholt: nein
Expired product administered No adverse event

Symptomtext

No additional AE reported; expired VAQTA was administered to one patient. Product expired 1/14/2023 and was administered today 1/24/2023.; This spontaneous report was received from a nurse referring to a patient of unknown age and gender. Information of the patient's medical history, concurrent condition and concomitant therapy was not reported. On 24-JAN-2023 (also reported as today), the patient was administrated with hepatitis a vaccine, inactivated (VAQTA) intramuscular injection 1 ml (lot #U021561, expiration date: 14-JAN-2023, strength, anatomical location and route of administration were not provided) for prophylaxis (expired product administered). The product was stored according to prescribing information through the date of administration. No additional adverse event (AE) details were available. No additional AE was reported.

Weitere VAERSDATA-Felder
Praegender Schweregrund
Expired product administered
Hospital-Tage
-
Labordaten
-
Aktuelle Erkrankungen
-
Vorgeschichte
-
Andere Medikamente
-
Allergien
-
Vorherige Impfungen
-

VAERS 2568188

MERCK & CO. INC. · HEP A (VAQTA) · Charge U021561

gering
Staat
NY
Alter
-
Geschlecht
U
Eingang
26.01.2023
Impfdatum
16.01.2023
Beginn
16.01.2023
Tage bis Beginn
0,0
Dosis
UNK
Route/Site
- / -
Tod: unbekannt Lebensbedrohlich: unbekannt Hospital: unbekannt Disable: unbekannt ER: unbekannt Erholt: nein
Expired product administered No adverse event

Symptomtext

No additional AE reported.; Customer reported expired VAQTA was administered to a patient.; This spontaneous report has been received from a nurse referring to a 57-year-old patient of unknown gender. The patient's pertinent medical history, concurrent conditions, previous drug reactions, allergies, or concomitant medications were not reported. On 16-JAN-2023 the patient has vaccinated with an expired dose of hepatitis a vaccine, inactivated(VAQTA SYRINGE (DEVICE)) 0.5 milligrams, for prophylaxis (lot #U021561 had been verified to be a valid number; expiration date 14-JAN-2023, and upon internal validation established as the same date) (vaccination scheme, frequency, route of administration, and anatomical site of injection were not reported) (expired product administered). There was no adverse effect reported.

Weitere VAERSDATA-Felder
Praegender Schweregrund
Expired product administered
Hospital-Tage
-
Labordaten
-
Aktuelle Erkrankungen
-
Vorgeschichte
-
Andere Medikamente
-
Allergien
-
Vorherige Impfungen
-

VAERS 2568331

MERCK & CO. INC. · HEP A (VAQTA) · Charge U021561

gering
Staat
KY
Alter
66,0
Geschlecht
F
Eingang
25.01.2023
Impfdatum
25.01.2023
Beginn
25.01.2023
Tage bis Beginn
0,0
Dosis
1
Route/Site
IM / LA
Tod: unbekannt Lebensbedrohlich: unbekannt Hospital: unbekannt Disable: unbekannt ER: unbekannt Erholt: ja
Expired product administered

Symptomtext

Adverse event: inadvertently administered expired Hep A vaccine. APRN inadvertently administered an expired vaccine to her patient because she failed to verify the expiration date on the vaccine vial before administration. Patient was monitored for 15 minutes after administration and did not experiences any adverse reactions to vaccine.

Weitere VAERSDATA-Felder
Praegender Schweregrund
Expired product administered
Hospital-Tage
-
Labordaten
-
Aktuelle Erkrankungen
-
Vorgeschichte
-
Andere Medikamente
-
Allergien
-
Vorherige Impfungen
-

VAERS 2565179

MERCK & CO. INC. · HEP A (VAQTA) · Charge U021561

gering
Staat
OH
Alter
66,0
Geschlecht
M
Eingang
22.01.2023
Impfdatum
21.01.2023
Beginn
21.01.2023
Tage bis Beginn
0,0
Dosis
1
Route/Site
IM / LA
Tod: unbekannt Lebensbedrohlich: unbekannt Hospital: unbekannt Disable: unbekannt ER: unbekannt Erholt: nein
Expired product administered

Symptomtext

It was noted after administration and after the patient had left, that the vaccine was expired by one week

Weitere VAERSDATA-Felder
Praegender Schweregrund
Expired product administered
Hospital-Tage
-
Labordaten
-
Aktuelle Erkrankungen
-
Vorgeschichte
-
Andere Medikamente
-
Allergien
-
Vorherige Impfungen
-

VAERS 2554711

GLAXOSMITHKLINE BIOLOGICALS · HEP A (HAVRIX) · Charge U021561

gering
Staat
WA
Alter
32,0
Geschlecht
M
Eingang
09.01.2023
Impfdatum
13.12.2022
Beginn
01.12.2022
Tage bis Beginn
-
Dosis
3
Route/Site
IM / RA
Tod: unbekannt Lebensbedrohlich: unbekannt Hospital: unbekannt Disable: unbekannt ER: unbekannt Erholt: ja
Extra dose administered No adverse event

Symptomtext

Patient received Hep A vaccine #2 and Hep B vaccine #3 on 12/8/22. Patient then received another Hep A and Hep B vaccine on 12/13/22 by a different nurse. No report signs or symptoms.

Weitere VAERSDATA-Felder
Praegender Schweregrund
Extra dose administered
Hospital-Tage
-
Labordaten
-
Aktuelle Erkrankungen
-
Vorgeschichte
-
Andere Medikamente
Olanzapine ODT 20mg Hydroxyzine pamoate 25mg Ibuprofen 400mg Clonidine 0.1mg Abilify 10mg
Allergien
Methylphenidate
Vorherige Impfungen
-

VAERS 2465744

MERCK & CO. INC. · HEP A (VAQTA) · Charge U021561

gering
Staat
TN
Alter
42,0
Geschlecht
F
Eingang
30.09.2022
Impfdatum
22.09.2022
Beginn
22.09.2022
Tage bis Beginn
0,0
Dosis
2
Route/Site
IM / LA
Tod: unbekannt Lebensbedrohlich: unbekannt Hospital: unbekannt Disable: unbekannt ER: unbekannt Erholt: unbekannt
Expired product administered No adverse event

Symptomtext

The patient received a Heplisav-B vaccine on 9/22/2022 that had expired on 9/17/2022. The patient did not experience any adverse events from the expired vaccine. She was notified of the incident.

Weitere VAERSDATA-Felder
Praegender Schweregrund
Expired product administered
Hospital-Tage
-
Labordaten
-
Aktuelle Erkrankungen
-
Vorgeschichte
-
Andere Medikamente
-
Allergien
-
Vorherige Impfungen
-

VAERS 2364347

MERCK & CO. INC. · HEP A (VAQTA) · Charge U021561

gering
Staat
MI
Alter
16,0
Geschlecht
U
Eingang
11.07.2022
Impfdatum
11.07.2022
Beginn
11.07.2022
Tage bis Beginn
0,0
Dosis
1
Route/Site
IM / RA
Tod: unbekannt Lebensbedrohlich: unbekannt Hospital: unbekannt Disable: unbekannt ER: unbekannt Erholt: nein
Incorrect dose administered

Symptomtext

Client was given one dose of adult Hep A vaccine instead of a pediatric dose. Mother advised and will be assessing for adverse signs/symptoms.

Weitere VAERSDATA-Felder
Praegender Schweregrund
Incorrect dose administered
Hospital-Tage
-
Labordaten
-
Aktuelle Erkrankungen
N/A
Vorgeschichte
N/A
Andere Medikamente
N/A
Allergien
N/A
Vorherige Impfungen
-

VAERS 2364345

MERCK & CO. INC. · HEP A (VAQTA) · Charge U021561

gering
Staat
MI
Alter
15,0
Geschlecht
F
Eingang
11.07.2022
Impfdatum
11.07.2022
Beginn
11.07.2022
Tage bis Beginn
0,0
Dosis
1
Route/Site
IM / LA
Tod: unbekannt Lebensbedrohlich: unbekannt Hospital: unbekannt Disable: unbekannt ER: unbekannt Erholt: nein
Incorrect dose administered

Symptomtext

Client was given dose of adult vaccine instead of pediatric dosage. Mother advised and will be assessing for adverse reaction signs/symptoms.

Weitere VAERSDATA-Felder
Praegender Schweregrund
Incorrect dose administered
Hospital-Tage
-
Labordaten
-
Aktuelle Erkrankungen
n/a
Vorgeschichte
n/a
Andere Medikamente
n/a
Allergien
n/a
Vorherige Impfungen
-

VAERS 2364340

MERCK & CO. INC. · HEP A (VAQTA) · Charge U021561

gering
Staat
MI
Alter
12,0
Geschlecht
M
Eingang
11.07.2022
Impfdatum
11.07.2022
Beginn
11.07.2022
Tage bis Beginn
0,0
Dosis
1
Route/Site
IM / LA
Tod: unbekannt Lebensbedrohlich: unbekannt Hospital: unbekannt Disable: unbekannt ER: unbekannt Erholt: nein
Extra dose administered

Symptomtext

Client was given adult dose of Hep A vaccine instead of pediatric dose. Clients mother was notified and will be assessing for signs/symptoms of adverse reactions.

Weitere VAERSDATA-Felder
Praegender Schweregrund
Extra dose administered
Hospital-Tage
-
Labordaten
-
Aktuelle Erkrankungen
n/a
Vorgeschichte
n/a
Andere Medikamente
n/a
Allergien
n/a
Vorherige Impfungen
-

VAERS 2315599

MERCK & CO. INC. · HEP A (VAQTA) · Charge U021561

gering
Staat
MI
Alter
1,1
Geschlecht
M
Eingang
10.06.2022
Impfdatum
10.06.2022
Beginn
10.06.2022
Tage bis Beginn
0,0
Dosis
1
Route/Site
IM / RL
Tod: unbekannt Lebensbedrohlich: unbekannt Hospital: unbekannt Disable: unbekannt ER: unbekannt Erholt: nein
Incorrect dose administered No adverse event

Symptomtext

No reported adverse reaction currently, discovered patient given adult dose of Hep A so received 1 ml and was due for 0.5 ml

Weitere VAERSDATA-Felder
Praegender Schweregrund
Incorrect dose administered
Hospital-Tage
-
Labordaten
none
Aktuelle Erkrankungen
none
Vorgeschichte
none
Andere Medikamente
none
Allergien
none
Vorherige Impfungen
-

VAERS 2278598

MERCK & CO. INC. · HEP A (VAQTA) · Charge U021561

gering
Staat
IN
Alter
17,0
Geschlecht
F
Eingang
16.05.2022
Impfdatum
16.05.2022
Beginn
16.05.2022
Tage bis Beginn
0,0
Dosis
1
Route/Site
IM / LA
Tod: unbekannt Lebensbedrohlich: unbekannt Hospital: unbekannt Disable: unbekannt ER: unbekannt Erholt: nein
Incorrect dose administered No adverse event Product administered to patient of inappropriate age

Symptomtext

No symptoms or adverse reaction reported. Patient received adult dose of Hepatitis A vaccine instead of pediatric dose. (Packaging similar and print on box and syringe very small).

Weitere VAERSDATA-Felder
Praegender Schweregrund
Incorrect dose administered
Hospital-Tage
-
Labordaten
None at this time
Aktuelle Erkrankungen
None
Vorgeschichte
None
Andere Medikamente
Unknown
Allergien
None
Vorherige Impfungen
-

VAERS 2264671

MERCK & CO. INC. · HEP A (VAQTA) · Charge U021561

gering
Staat
TN
Alter
24,0
Geschlecht
M
Eingang
05.05.2022
Impfdatum
05.05.2022
Beginn
05.05.2022
Tage bis Beginn
0,0
Dosis
3
Route/Site
IM / RA
Tod: unbekannt Lebensbedrohlich: unbekannt Hospital: unbekannt Disable: unbekannt ER: unbekannt Erholt: ja
Extra dose administered

Symptomtext

Pt was in for a visit and stated he needed his 2nd Hep A vaccine. The immunization screen was showing only 1 previous dose and the forcast was showing he was due for his 2nd Hep A. The vaccine was ordered and administered per protocol. After pt left the clinic, I noticed on the front screen that the patient had received a 2nd Hep A on 8/10/20 that was never entered on his immunization screen. Therefore the patient received an extra dose of Hep A.

Weitere VAERSDATA-Felder
Praegender Schweregrund
Extra dose administered
Hospital-Tage
-
Labordaten
no tests were required. Pt tolerated the vaccine well.
Aktuelle Erkrankungen
NONE
Vorgeschichte
NONE
Andere Medikamente
NONE
Allergien
NKDA
Vorherige Impfungen
-